Expert Rev Clin Immunol. 2021 Apr 20. doi: 10.1080/1744666X.2021.1919086. Online ahead of print.
ABSTRACT
INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a dysregulated hyperinflammatory response.
AREAS COVERED: The authors review evidence on IL-6 and IL-6 blockade in coronavirus disease 2019 (COVID-19) and discuss the pathophysiological and prognostic roles of this cytokine and the clinical impact of pharmacological blockade of IL-6 blockade. Material includes original articles and reviews published from March 2020 to March 2021 and searched on PubMed, medRxiv, and bioRxiv.
EXPERT OPINION: IL-6 is one the most prominent inflammatory cytokines. Increased levels were recorded in COVID-19 patients, especially those with severe-to-critical disease. Evidence is accumulating on the relevance of IL-6 as a prognostic marker in COVID-19, including need for mechanical ventilation and death. Since IL-6 is a druggable target for several inflammatory diseases, blockers of the IL-6 signaling pathway were repurposed to block the abnormal SARS-CoV-2-induced cytokine release. Data are limited to few randomized controlled trials that reported encouraging, though not conclusive, results, indicating the usefulness of IL-6 blockade early in the course of disease in patients with hyperinflammation and no or limited organ damage. Further research is warranted to explore the role of IL-6 in different COVID-19 phenotypes and identify subgroups of patients who may mostly benefit from IL-6 pathway inhibition.
PMID:33874829 | DOI:10.1080/1744666X.2021.1919086